Site Search
311 Results (showing 1 - 25)
Jan 30, 2004
PerkinElmer Reports Revenues, Income on Rise
PerkinElmer this week reported revenues of $432.6 million for the fourth quarter of 2003, up from $410 million for the same period in 2002.
Jan 30, 2004
At A Glance
Name: Markus Kalkum
Position: Assistant professor, Beckman Research Institute, City of Hope, Duarte, Calif., since June 2003.
Jan 30, 2004
Recently, RNAi News incorrectly listed the number of a US patent application entitled “Recombinant Gene Containing Inverted Repeat Sequence and Utilization Thereof” as 20040010131.
Jan 30, 2004
David Allis and Phillip Sharp
Premium
The Wiley Foundation said this week that Rockefeller University researcher David Allis has been named the recipient of the third annual Wiley Prize in the Biomedical Sciences.
Jan 30, 2004
This week, Alnylam announced that its Ribopharma unit has granted a non-exclusive license to the Kreutzer-Limmer patent, a European patent that covers “a medicament containing at least one double-stranded oligonucleotide (dsRNA) designed to inhibit the expression of a target gene,” t
Jan 30, 2004
Waters this week reported a 30 percent decrease in fourth quarter 2003 mass spec sales year-over-year amidst reports of layoffs and the announcement that it would acquire a second information systems company, NuGenesis, for $43 million...Subscribers: click headline for more
Jan 30, 2004
Last week, when AIDS researcher David Ho published a retraction in Science of some results from a proteomics experiment describing the discovery of a group of proteins with purported anti-HIV activity...Subscribers: click headline for more
Jan 30, 2004
UK Proteomics innovators listen up: As much as 10 million ($18.3 million) in government funding is available for those who are searching for radical solutions to analyzing the proteome,"...Subscribers: click headline for more
Jan 30, 2004
US Patent No. 6,682,942. Microdevices for screening biomolecules. Inventors: Peter Wagner, Dana Ault-Riche, Steffen Nock, Christian Itin. Assignee: Zyomyx.
Jan 30, 2004
More than a year after it began putting together a plan to establish a new RNAi research group, the NCI s Center for Cancer Research has named Natasha Caplen as director of the program, RNAi News has learned....Subscribers: click headline for more
Jan 30, 2004
At A Glance
Name: James Birchler
Position: Professor of biological sciences, University of Missouri
Jan 30, 2004
Qiagen has released two new assay kits for detecting tyrosine kinase and serine/threonine kinase activity without radioactivity. The LiquiChip Broad-Range Kinase kits consist of kinase substrates immobilized on LiquiChip beads.
Jan 30, 2004
Herbert Fritsche, James Mullen
Premium
Herbert Fritsche has joined the scientific advisory board of Health Discovery, of Waco Texas. Fritsche is currently a professor of laboratory medicine and chief of the clinical chemistry section at The University of Texas, M.D.
Jan 30, 2004
Last spring, Benitec initiated a reorganization plan -- designed to turn it into a US-based and publicly traded RNAi drug developer -- by exclusively licensing to Promega its DNA-directed RNAi technology for areas outside of human therapeutics....Subscribers: click headline for more
Jan 30, 2004
It seems that in most cases, big pharma is maintaining a wait-and-see attitude on RNAi-based drugs and will continue to rely on small- molecule approaches to therapeutics....Subscribers: click headline for more
Jan 30, 2004
BD Biosciences Clontech recently announced that it has launched RNAi-Ready pSIREN-RetroQ-ZsGreen and pSIREN-DNR-DsRedExpress vectors, which provide fluorescent markers for monitoring the efficacy of gene silencing construct delivery.
Jan 30, 2004
Genta Says Aventis Takeover Won’t Change Terms of Genasense Deal
Jan 29, 2004
Taking its first step in the burgeoning animal traceability market, Orchid Biosciences this week said it will help one of Canada s largest pork distributors genotype its sows...Subscribers: click headline for more
Jan 29, 2004
ABI Posts Increased Revenues in Q2 …
Applied Biosystems this week said that total revenue in its second quarter for fiscal 2004 increased to $458.4 million from $444.7 million for the same period a year ago.
Jan 29, 2004
Personalized medicine should be a matter of personal choice...Subscribers: click headline for more